Gene Editing CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
4
CDMOs tracked
4
Fully scored
3
With FDA records
12
FDA inspections
13
EMA/MHRA GMP certs

Gene editing CDMOs support CRISPR, base, and prime editing programs — spanning guide RNA and nuclease (mRNA or protein) supply, delivery (LNP, AAV, or electroporation), and, for ex vivo programs, edited-cell manufacturing.

Because a gene-editing program touches several modalities at once, CDMO selection often hinges on which steps a partner covers in-house versus coordinates. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 7 NAI (no action), 5 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (10), France (4), Germany (3), Ireland (3), UNITED KINGDOM (3).

Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
2
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
3
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
4
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
77.3 92.9 2 insp · 0 GMP 2025-03-14 · NAI — 34 programs
How we score CDMOs →

What to evaluate in a Gene Editing CDMO

Editing components
Confirm supply of guide RNA and nuclease (Cas mRNA or protein) — in-house or sourced — and the quality controls on each.
Delivery modality
In vivo editing needs LNP or AAV delivery; ex vivo needs electroporation and cell handling. Match the CDMO's delivery experience to your approach.
Ex vivo cell manufacturing
For edited cell therapies, evaluate closed-system cell processing and chain-of-identity, as with other cell therapies.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Gene Editing CDMOs — Frequently Asked Questions

How many Gene Editing CDMOs have FDA inspection records?
CDMO Signal tracks 3 Gene Editing CDMOs with FDA inspection records and 13 EMA/MHRA GMP certificates across the group.
What should I look for in a gene editing CDMO?
Map the steps you need — guide RNA and nuclease supply, delivery (LNP/AAV/electroporation), and edited-cell manufacturing — and confirm which the CDMO covers in-house versus coordinates, plus a clean FDA and EMA/MHRA record.
Why do gene editing programs use multiple CDMOs?
A single program may need guide RNA, a nuclease, a delivery vehicle, and cell manufacturing — distinct capabilities. Some CDMOs cover several in-house; many programs combine specialists.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs mRNA / LNP CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector